U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
Colistimethate is a methanesulfonate of polymyxin antibacterial colistin. Colistimethate is a nonactive prodrug. In aqueous solutions, colistimethate is hydrolyzed and forms a complex mixture of partially sulfomethylated derivatives and colistin. The antimicrobial activity of colistin is similar to that of polymyxin B and is restricted to gram-negative bacteria, including P aeruginosa, Acinetobacter species, Enterobacter-Klebsiella tribe, Escherichia coli, Salmonella and Shigella species, Citrobacter species, Yersinia pseudotuberculosis, Morganella morganii and Haemophilus influenzae. Colistin has also been shown to possess considerable in vitro activity against Stenotrophomonas maltophilia. Colistin and polymyxin B, however, do not have activity against Proteus, Providencia, Serratia species, Pseudomonas mallei, Burkholderia cepacia, Brucella species, most gram-positive bacteria, gram-negative cocci, anaerobes, fungi and parasites. Parenteral or nebulized colistimethate is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
COLY-MYCIN M

Approved Use

Colistimethate for injection is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. This antibiotic is not indicated for infections due to Proteus or Neisseria. Colistimethate for injection has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Colistimethate for injection may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of colistimethate for injection and other antibacterial drugs, colistimethate for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Launch Date

1.33056E10
PubMed

PubMed

TitleDatePubMed
[Recovery after hemodialysis in 2 cases of acute renal insufficiency during treatment with kanamycin and colistin methanesulfonate].
1970 Apr 27
Nonoliguric renal failure secondary to sodium colistimethate: a report of four cases.
1971 Aug

Sample Use Guides

Either 75 mg or 150 mg twice a day by nebulization. Parenteral should be given in 2 to 4 divided doses at dose levels of 2.5 to 5 mg/kg per day for patients with normal renal function, depending on the severity of the infection.
Route of Administration: Other
Substance Class Mixture
Created
by admin
on Fri Dec 15 15:59:04 UTC 2023
Edited
by admin
on Fri Dec 15 15:59:04 UTC 2023
Record UNII
XW0E5YS77G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
COLISTIMETHATE SODIUM
EP   GREEN BOOK   INN   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
colistimethate sodium [INN]
Common Name English
COLISTIN SODIUM METHANESULFONATE [JAN]
Common Name English
COLOMYCIN
Brand Name English
COLISTIN SODIUM METHANESULFONATE [MI]
Common Name English
W 1929
Code English
METHACOLIMYCIN
Brand Name English
COLIMICINA
Brand Name English
COLISTIMETHATE SODIUM [USAN]
Common Name English
COLY-MYCIN
Brand Name English
COLISTIMETHATE SODIUM [EP MONOGRAPH]
Common Name English
COLISTIMETHATE SODIUM [ORANGE BOOK]
Common Name English
COLISTIN SULPHOMETHATE
Common Name English
COLISTIN METHANESULFONATE SODIUM
Common Name English
COLISTIMETHATE SODIUM [USP-RS]
Common Name English
NSC-756688
Code English
COLISTIN SODIUM METHANESULFONATE
MI  
Common Name English
COLIMYCINE
Brand Name English
PROMIXIN
Brand Name English
W-1929
Code English
COLISTIMETHATE SODIUM [GREEN BOOK]
Common Name English
COLISTIMETHATE SODIUM [VANDF]
Common Name English
COLIMYCIN
Brand Name English
SODIUM COLISTIMETHATE
Common Name English
Colistimethate sodium [WHO-DD]
Common Name English
ALFICETIN
Brand Name English
COLISTIN SODIUM METHANESULPHONATE
Common Name English
Pentasodium colistinmethanesulfonate
Common Name English
COLISTIMETHATE SODIUM [USP MONOGRAPH]
Common Name English
COLISTIMETHATE SODIUM [MART.]
Common Name English
PENTASODIUM COLISTINMETHANESULPHONATE
Common Name English
Classification Tree Code System Code
CFR 21 CFR 522.468
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
EU-Orphan Drug EU/3/02/088
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
NCI_THESAURUS C52588
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
FDA ORPHAN DRUG 672418
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
EMA ASSESSMENT REPORTS COLOBREATHE (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
Code System Code Type Description
FDA UNII
XW0E5YS77G
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
ChEMBL
CHEMBL1201441
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
MERCK INDEX
m3733
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY Merck Index
CHEBI
34650
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
DRUG CENTRAL
731
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
CAS
21362-08-3
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
SUPERSEDED
ECHA (EC/EINECS)
232-516-9
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
EPA CompTox
DTXSID6045822
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
CAS
8068-28-8
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
RXCUI
48305
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY RxNorm
NSC
756688
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
NCI_THESAURUS
C65349
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
INN
5642
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
DRUG BANK
DB01111
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
RS_ITEM_NUM
1147009
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
EVMPD
SUB06801MIG
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
DAILYMED
XW0E5YS77G
Created by admin on Fri Dec 15 15:59:04 UTC 2023 , Edited by admin on Fri Dec 15 15:59:04 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY
Definition References